- In April 2023, Zydus Lifesciences Limited obtained FDA approval for its 500mg oral azithromycin tablets. This medication is used for treating various bacterial infections, including pneumonia, bronchitis, and sexually transmitted diseases such as chancroid. The approval enhances Zydus's portfolio in the U.S. market, offering a reliable option for managing such infections effectively
- In May 2021, Teva Pharmaceutical Industries Ltd. launched its Generic Erythromycin Tablets USP in the U.S. The tablets are indicated for treating a broad range of bacterial infections, including chancroid. With the launch, Teva expanded its generic portfolio, providing an affordable alternative for patients requiring effective antibiotic treatment for various bacterial conditions
- In April 2020, Alembic Limited introduced Zithromax, a generic version of azithromycin, in both 250mg and 500mg doses. This product is designed to treat a range of bacterial infections, including chlamydia. The launch marked a significant step for Alembic in expanding its presence in the U.S. generic antibiotic market, addressing unmet medical needs
- In February 2020, Aurobindo Pharma received FDA approval to manufacture and market oral azithromycin tablets in the U.S. The drug is used to treat mild to moderate bacterial infections, including chancroid. This approval allowed Aurobindo to strengthen its product portfolio in the U.S., providing a crucial treatment option for a variety of infections
